Brian Abrahams
Stock Analyst at RBC Capital
(1.52)
# 3,261
Out of 4,869 analysts
454
Total ratings
39.66%
Success rate
-11%
Average return
Main Sectors:
Stocks Rated by Brian Abrahams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $423 → $420 | $440.87 | -4.73% | 53 | Jun 17, 2025 | |
| MLTX MoonLake Immunotherapeutics | Reiterates: Outperform | $67 | $43.50 | +54.02% | 2 | Jun 3, 2025 | |
| NBIX Neurocrine Biosciences | Reiterates: Outperform | $145 | $126.55 | +14.58% | 20 | Jun 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Outperform | $943 | $509.72 | +85.00% | 32 | May 27, 2025 | |
| CTNM Contineum Therapeutics | Reiterates: Outperform | $31 | $4.76 | +551.26% | 5 | May 15, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Outperform | $21 → $20 | $11.13 | +79.69% | 3 | May 15, 2025 | |
| APLT Applied Therapeutics | Reiterates: Sector Perform | $1.5 | $0.34 | +337.45% | 6 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $34 → $33 | $4.42 | +646.61% | 12 | May 13, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $58 → $55 | $32.06 | +71.55% | 14 | May 13, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Sector Perform | $87 → $58 | $20.08 | +188.84% | 34 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $58 | $50.20 | +15.54% | 20 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $58 | $8.24 | +603.88% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 → $13 | $10.10 | +28.71% | 18 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $217 → $205 | $127.04 | +61.37% | 36 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $64 → $67 | $68.46 | -2.13% | 21 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $84 | $34.00 | +147.06% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $12.31 | +151.83% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $4 → $3 | $1.28 | +134.38% | 13 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $0.79 | +409.10% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $24 → $20 | $5.72 | +249.65% | 10 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $84 → $90 | $108.50 | -17.05% | 31 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $139 → $143 | $100.69 | +42.02% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $17.96 | +122.72% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $20 → $1.5 | $1.17 | +28.21% | 15 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $48 → $2 | $1.26 | +59.36% | 11 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Perform | $4 | $9.30 | -56.99% | 21 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $32 → $30 | $27.43 | +9.37% | 11 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $13 → $12 | $10.08 | +19.05% | 14 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $7.05 | +212.06% | 9 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $15 | $7.18 | +108.91% | 14 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $9 | $2.48 | +262.90% | 3 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $33 | $53.11 | -37.86% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $37.14 | - | 4 | Dec 4, 2017 |
Vertex Pharmaceuticals
Jun 17, 2025
Maintains: Sector Perform
Price Target: $423 → $420
Current: $440.87
Upside: -4.73%
MoonLake Immunotherapeutics
Jun 3, 2025
Reiterates: Outperform
Price Target: $67
Current: $43.50
Upside: +54.02%
Neurocrine Biosciences
Jun 2, 2025
Reiterates: Outperform
Price Target: $145
Current: $126.55
Upside: +14.58%
Regeneron Pharmaceuticals
May 27, 2025
Reiterates: Outperform
Price Target: $943
Current: $509.72
Upside: +85.00%
Contineum Therapeutics
May 15, 2025
Reiterates: Outperform
Price Target: $31
Current: $4.76
Upside: +551.26%
Aardvark Therapeutics
May 15, 2025
Maintains: Outperform
Price Target: $21 → $20
Current: $11.13
Upside: +79.69%
Applied Therapeutics
May 14, 2025
Reiterates: Sector Perform
Price Target: $1.5
Current: $0.34
Upside: +337.45%
Karyopharm Therapeutics
May 13, 2025
Maintains: Outperform
Price Target: $34 → $33
Current: $4.42
Upside: +646.61%
Xenon Pharmaceuticals
May 13, 2025
Maintains: Outperform
Price Target: $58 → $55
Current: $32.06
Upside: +71.55%
Sarepta Therapeutics
May 7, 2025
Maintains: Sector Perform
Price Target: $87 → $58
Current: $20.08
Upside: +188.84%
May 7, 2025
Maintains: Outperform
Price Target: $57 → $58
Current: $50.20
Upside: +15.54%
May 7, 2025
Maintains: Outperform
Price Target: $65 → $58
Current: $8.24
Upside: +603.88%
May 6, 2025
Reiterates: Outperform
Price Target: $11 → $13
Current: $10.10
Upside: +28.71%
May 2, 2025
Maintains: Outperform
Price Target: $217 → $205
Current: $127.04
Upside: +61.37%
Apr 30, 2025
Maintains: Sector Perform
Price Target: $64 → $67
Current: $68.46
Upside: -2.13%
Apr 22, 2025
Reiterates: Outperform
Price Target: $84
Current: $34.00
Upside: +147.06%
Mar 7, 2025
Initiates: Outperform
Price Target: $31
Current: $12.31
Upside: +151.83%
Mar 4, 2025
Maintains: Sector Perform
Price Target: $4 → $3
Current: $1.28
Upside: +134.38%
Mar 4, 2025
Reiterates: Sector Perform
Price Target: $4
Current: $0.79
Upside: +409.10%
Feb 21, 2025
Maintains: Sector Perform
Price Target: $24 → $20
Current: $5.72
Upside: +249.65%
Feb 12, 2025
Maintains: Sector Perform
Price Target: $84 → $90
Current: $108.50
Upside: -17.05%
Feb 3, 2025
Maintains: Outperform
Price Target: $139 → $143
Current: $100.69
Upside: +42.02%
Jan 28, 2025
Reiterates: Outperform
Price Target: $40
Current: $17.96
Upside: +122.72%
Jan 10, 2025
Downgrades: Sector Perform
Price Target: $20 → $1.5
Current: $1.17
Upside: +28.21%
Dec 20, 2024
Downgrades: Sector Perform
Price Target: $48 → $2
Current: $1.26
Upside: +59.36%
Nov 21, 2024
Upgrades: Sector Perform
Price Target: $4
Current: $9.30
Upside: -56.99%
Nov 1, 2024
Maintains: Sector Perform
Price Target: $32 → $30
Current: $27.43
Upside: +9.37%
Aug 6, 2024
Maintains: Sector Perform
Price Target: $13 → $12
Current: $10.08
Upside: +19.05%
Jun 5, 2024
Reiterates: Outperform
Price Target: $22
Current: $7.05
Upside: +212.06%
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $7.18
Upside: +108.91%
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $2.48
Upside: +262.90%
Nov 3, 2021
Maintains: Sector Perform
Price Target: $21 → $33
Current: $53.11
Upside: -37.86%
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $37.14
Upside: -